AstraZeneca, Sanofi, Sobi simplify contractual agreements for Nirsevimab Ruchika Sharma12 April 2023 3:44 PM ISTBeyfortus (nirsevimab), an investigational long-acting antibody designed to protect all infants against RSV infections from birth through their first...
Pfizer RSV vaccine 82 percent effective in severe infection in infants: Data Ruchika Sharma7 April 2023 12:30 PM ISTFDA approval could make Pfizer's shot the first maternal vaccine available to prevent the disease in infants.
Monoclonal antibody treatment improves outcomes of respiratory syncytial virus infection outcomes in infants Jacinthlyn Sylvia20 Feb 2023 10:15 AM ISTWithout a discernible increase in adverse events, nirsevimab, motavizumab, and palivizumab were linked to significant improvements in the prevention...
USFDA accepts AstraZeneca’s BLA for Nirsevimab for prevention of RSV lower respiratory tract disease Ruchika Sharma7 Jan 2023 10:00 AM ISTRSV is a very contagious virus that can lead to serious respiratory illness, according to the Centers for Disease Control and Prevention.
Sanofi gets European Commission nod for Beyfortus to prevent RSV disease in infants Ruchika Sharma5 Nov 2022 3:00 PM ISTRSV is the most common cause of LRTI, including bronchiolitis and pneumonia, in infants.
EMA Committee recommends nod of Sanofi, AstraZeneca Beyfortus for prevention of RSV disease in infants Ruchika Sharma18 Sept 2022 3:00 PM ISTParis: Sanofi and AstraZeneca have recently announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has...
